Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Guardant Health, Inc.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Guardant Health, Inc.

Regulatory records
26
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 26 FDA records to the applicant name Guardant Health, Inc.. It includes 3 original PMA approvals. 9 entries are PMA supplements. 14 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Aug 7, 2020 to Oct 5, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code PHP appears in 13 of the 26 linked filings. The collection spans 2 FDA product codes and 3 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P230009, with 13 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.

Applicant mailing address recorded by FDA: 3000 Hanover St., Palo Alto, CA, 94304. Recorded on P230009/S021, decision dated Oct 5, 2026.

Changes described in PMA records

P230009/S021: Shield

FDA’s recorded scope: approval of a secondary vendor

Oct 5, 2026 · 30-Day Notice

P200010/S029: Guardant360 CDx

FDA’s recorded scope: Approval for expanding the intended use and indications for use of Guardant360 CDx to include a companion diagnostic indication for the detection of ESR1 mutations in Breast Cancer (BC) patients who may benefit from treatment with INLURIYO (imlunestrant) in combination with VERZENIO (abemaciclib).

Sep 18, 2026 · Normal 180 Day Track

P200010/S024: Guardant360 CDx

FDA’s recorded scope: Approval for expanding the indications for use to include a companion diagnostic claim for the detection of ESR1 mutations in patients with breast cancer who may benefit from treatment with ETCAMAH (camizestrant).

Sep 4, 2026 · Normal 180 Day Track

P200010/S032: Guardant360 CDx

FDA’s recorded scope: Approval of the clinical protocol titled Clinical Validation of Guardant360 CDx for the Selection of First-Line Non-Small Cell Lung Cancer (NSCLC) Patients with ERBB2/HER2 TKD-Activating Mutations for Zongertinib Therapy (Protocol No. 01-LU-038, PLP-003941 R1, Version 1.0) for the post-approval study.

Aug 7, 2026 · Normal 180 Day Track No User Fee

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

  1. Shield

    P230009/S021 · PMA supplement
  2. Guardant360 CDx

    P200010/S029 · PMA supplement
  3. Shield

    P230009/S020 · PMA supplement
  4. Guardant360 CDx

    P200010/S024 · PMA supplement
  5. Guardant360 CDx

    P200010/S032 · PMA supplement
  6. Shield

    P230009/S010 · PMA supplement
  7. Shield

    P230009/S018 · PMA supplement
  8. Guardant360 CDx

    P200010/S030 · PMA supplement
  9. Guardant360 CDx

    P200010/S031 · PMA supplement
  10. Guardant360 Liquid CDx

    P250027/S001 · PMA supplement
  11. Guardant360 CDx

    P200010/S027 · PMA supplement
  12. Shield

    P230009/S016 · PMA supplement
  13. Guardant360 Liquid CDx

    P250027 · PMA decision
  14. Guardant360 CDx

    P200010/S025 · PMA supplement
  15. Shield

    P230009/S014 · PMA supplement
  16. Shield

    P230009/S015 · PMA supplement
  17. Shield

    P230009/S013 · PMA supplement
  18. Guardant360 CDx

    P200010/S026 · PMA supplement
  19. Guardant360 CDx

    P200010/S028 · PMA supplement
  20. Shield

    P230009/S011 · PMA supplement
  21. Shield

    P230009/S009 · PMA supplement
  22. Guardant360 CDx

    P200010/S021 · PMA supplement
  23. Shield

    P230009/S008 · PMA supplement
  24. Shield

    P230009/S007 · PMA supplement
  25. Shield

    P230009 · PMA decision
  26. Guardant360 CDx

    P200010 · PMA decision
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.